ONYX BIOTEC LIMITED Valuation
ONYX · Healthcare · Current price ₹37.6
Is ONYX BIOTEC LIMITED undervalued?
DocStoX estimates the fair value of ONYX BIOTEC LIMITED at ₹30 per share, versus the current market price of ₹38. That puts the stock about -20.2% above our fair-value estimate, which we read as "Expensive". Our confidence in this estimate is low.
How this fair value is calculated
This estimate blends 1 independent method: Residual income (₹30). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹26 (bear) to ₹30 (base) to ₹35 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
Valuation multiples
ONYX BIOTEC LIMITED trades at a P/E of 13.8x and a P/B of 1.2x, with a dividend yield of 0.0%. Multiples are most useful compared against the company's own history and its sector peers — see the peer comparison for context.
Understand the ratios
More on ONYX BIOTEC LIMITED
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.